Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients With IgG4-Related Disease

NCT04602598 is registered in ClinicalTrials.gov with Matthew C. Baker as lead sponsor.

NCT NCT04602598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04602598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients With IgG4-Related Disease
Lead sponsor
Matthew C. Baker
Phase
Phase 2
Overall status
Completed
Start date
August 1, 2022
Completion date
April 3, 2025
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

igg4 related disease